BBIO vs. NEM
BBIO (BridgeBio Pharma, Inc.) and NEM (Newmont Corporation) are both stocks. BBIO operates in Biotechnology (Healthcare), while NEM operates in Gold (Basic Materials). Over the past 5 years, BBIO returned 1.89%/yr vs 10.33%/yr for NEM. At a 0.11 correlation, their price movements are largely independent.
Performance
BBIO vs. NEM - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BBIO achieves a -11.92% return, which is significantly lower than NEM's -0.43% return.
BBIO
- 1D
- -0.35%
- 1M
- -0.03%
- YTD
- -11.92%
- 6M
- -9.25%
- 1Y
- 74.44%
- 3Y*
- 61.48%
- 5Y*
- 1.89%
- 10Y*
- —
NEM
- 1D
- -0.72%
- 1M
- -14.84%
- YTD
- -0.43%
- 6M
- 11.71%
- 1Y
- 91.07%
- 3Y*
- 36.63%
- 5Y*
- 10.33%
- 10Y*
- 13.46%
BBIO vs. NEM - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
BBIO BridgeBio Pharma, Inc. | -11.92% | 178.75% | -32.03% | 429.79% | -54.32% | -76.54% | 102.88% | 27.22% |
NEM Newmont Corporation | -0.43% | 172.82% | -7.83% | -8.76% | -20.77% | 7.40% | 40.28% | 14.93% |
Correlation
The correlation between BBIO and NEM is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.13 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.13 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.12 |
Correlation (All Time) Calculated using the full available price history since Jun 28, 2019 | 0.11 |
Fundamentals
BBIO:
-$3.76
NEM:
$6.34
BBIO:
23.00
NEM:
4.77
BBIO:
$566.04M
NEM:
$17.23B
BBIO:
$538.20M
NEM:
$8.97B
BBIO:
-$602.24M
NEM:
$13.78B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BBIO vs. NEM — Risk / Return Rank
BBIO
NEM
BBIO vs. NEM - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for BridgeBio Pharma, Inc. (BBIO) and Newmont Corporation (NEM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BBIO | NEM | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.35 | ||
| Sortino ratioReturn per unit of downside risk | +0.01 | ||
| Omega ratioGain probability vs. loss probability | 1.30 | 1.32 | -0.02 |
| Calmar ratioReturn relative to maximum drawdown | 3.70 | 3.36 | +0.34 |
| Martin ratioReturn relative to average drawdown | 9.25 | 8.94 | +0.31 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| BBIO | NEM | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.60 | 1.96 | -0.35 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.02 | 0.27 | -0.25 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.38 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.16 | 0.12 | +0.04 |
Drawdowns
BBIO vs. NEM - Drawdown Comparison
The maximum BBIO drawdown since its inception was -92.80%, which is greater than NEM's maximum drawdown of -81.30%. Use the drawdown chart below to compare losses from any high point for BBIO and NEM.
Loading charts...
Drawdown Indicators
| BBIO | NEM | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.80% | -81.30% | -11.50% |
Max Drawdown (1Y)Largest decline over 1 year | -20.25% | -27.25% | +7.00% |
Max Drawdown (3Y)Largest decline over 3 years | -49.08% | -36.57% | -12.51% |
Max Drawdown (5Y)Largest decline over 5 years | -91.89% | -62.40% | -29.49% |
Max Drawdown (10Y)Largest decline over 10 years | — | -62.40% | — |
Current DrawdownCurrent decline from peak | -15.69% | -24.65% | +8.96% |
Average DrawdownAverage peak-to-trough decline | -45.80% | -41.38% | -4.42% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.07% | 10.22% | -2.15% |
Volatility
BBIO vs. NEM - Volatility Comparison
The current volatility for BridgeBio Pharma, Inc. (BBIO) is 12.10%, while Newmont Corporation (NEM) has a volatility of 14.19%. This indicates that BBIO experiences smaller price fluctuations and is considered to be less risky than NEM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BBIO | NEM | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.10% | 14.19% | -2.09% |
Volatility (6M)Calculated over the trailing 6-month period | 34.41% | 36.93% | -2.52% |
Volatility (1Y)Calculated over the trailing 1-year period | 46.75% | 46.87% | -0.12% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 85.95% | 37.83% | +48.12% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 83.80% | 35.59% | +48.21% |
Dividends
BBIO vs. NEM - Dividend Comparison
BBIO has not paid dividends to shareholders, while NEM's dividend yield for the trailing twelve months is around 1.03%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BBIO BridgeBio Pharma, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NEM Newmont Corporation | 1.03% | 1.00% | 2.69% | 3.87% | 4.66% | 3.55% | 1.74% | 3.31% | 1.62% | 0.67% | 0.37% | 0.56% |
Financials
BBIO vs. NEM - Financials Comparison
This section allows you to compare key financial metrics between BridgeBio Pharma, Inc. and Newmont Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
BBIO and NEM have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NEM has higher volatility (14.19%) compared to BBIO (12.10%). In terms of maximum drawdown, BBIO dropped -92.80% vs NEM's -81.30%.
NEM currently has the higher Sharpe Ratio (1.96 vs 1.60), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BBIO and NEM
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer